Navigating the treatment landscape in multiple myeloma: which combinations to use and when?

Introduction

Multiple myeloma (MM) is a clonal plasma cell disorder that accounts for approximately 10% of hematological malignancies [ 1 ]. The disease has an estimated incidence of 4.5–6.0 per 100,000 people per year in Europe and primarily affects elderly patients, with a median age at diagnosis of 72 years [ 1 ]. Although MM remains an incurable disease, the development and introduction of therapies such as the immunomodulatory drugs thalidomide and lenalidomide and the proteasome inhibitor bortezomib have led to improved overall survival (OS) [ 2 , 3 ]. Recent years have also seen the development and approval of numerous new treatments for patients with MM, including the second-generation proteasome inhibitors carfilzomib and ixazomib, of which carfilzomib demonstrated improved survival in a head-to-head study of carfilzomib plus dexamethasone versus bortezomib plus dexamethasone [ 4 ]. Other therapies with different mechanisms of action have emerged, including the immunomodulatory agent pomalidomide, the alkylating agent bendamustine, the histone deacetylase (HDAC) inhibitor panobinostat, and the monoclonal antibodies elotuzumab and daratumumab [ 5 , 6 ]. Results from clinical trials suggest that the use of these agents may help to improve outcomes further [ 7 – 16 ].

Given the dramatic increase in therapeutic options available for patients with MM, one of the main challenges for physicians and funding bodies is deciding which agents to use and in which order and/or combination [ 17 , 18 ]. Clonal heterogeneity is often observed in patients with MM, and it has been suggested that suboptimal treatment may lead to eradication of sensitive subclones while allowing resistant clones to expand [ 19 ]. As a result, combination therapy using agents from different drug classes with distinct and synergistic mechanisms of action is increasingly being utilized in an attempt to remove more subclonal groups, to reduce the risk of developing drug resistance and to induce a deeper response [ 5 , 19 ]. For example, preclinical and clinical data suggest that a synergistic effect is observed when immunomodulatory drugs and proteasome inhibitors or monoclonal antibodies are used in combination [ 7 , 10 , 16 , 20 – 22 ]. Immunomodulatory drugs stimulate natural killer cells and proteasome inhibitors may enhance natural killer cell-mediated cytotoxicity by reducing expression of host protein fragments on major histocompatibility complex (MHC) class I molecules [ 20 ]. In addition, monoclonal antibodies induce cell death via a number of mechanisms including antibody-dependent cell-mediated cytotoxicity (ADCC) and immunomodulatory drugs may enhance this anti-myeloma activity by activating the effector cells of ADCC [ 22 ]. However, when making treatment decisions, it is important to consider patient-related factors (i.e., age, comorbidities, and eligibility for autologous stem cell transplantation (ASCT)), disease-related factors (i.e., cytogenetics, disease burden, and aggressiveness of relapse in the relapsed/refractory disease setting) and previous therapies (i.e., number of previous therapy lines, response to previous therapies, and tolerability to previous therapies) [ 5 , 17 , 23 ]. Physicians also need to consider the balance between increasing the depth of response from a drug regimen and exposing patients to increased toxicity [ 24 ]. Although a deeper response is associated with better long-term outcomes [ 11 , 14 , 25 , 26 ], the intensive multidrug therapy required to achieve this goal may result in significant treatment-related toxicity. Furthermore, the primary aim of treatment may differ between the newly diagnosed and relapsed/refractory settings, and this may influence the choice of drug regimen.

In this article, we review available therapies and provide guidance on the use of various treatment options in the newly diagnosed and relapsed/refractory settings. In addition, considerations for patients who are not eligible for ASCT are discussed, as well as for those who have high-risk disease.

Management of patients with newly diagnosed multiple myeloma

Transplant-eligible patients

Treatment decisions in patients with newly diagnosed MM (NDMM) are usually made on the basis of age, performance status, and comorbidities. It is also important to take the patient’s preference into account [ 24 ]. In Europe, the standard of care for first-line therapy in patients up to 65 years of age and those considered to be in good clinical condition is induction therapy followed by high-dose melphalan and ASCT [ 1 , 17 ]. The goals of induction therapy are to induce a deep response prior to ASCT, and this typically involves the use of combinations of two or three drugs in fit, transplant-eligible patients (Fig. 1 ) [ 1 , 17 , 24 ]. Fig. 1 Treatment algorithm for patients with newly diagnosed multiple myeloma. ASCT , autologous stem cell transplantation; CD , cyclophosphamide and dexamethasone; CPR , cyclophosphamide, prednisone, and lenalidomide; CTD , cyclophosphamide, thalidomide, and dexamethasone; MM , multiple myeloma; MP , melphalan and prednisone; MPR , melphalan, prednisone, and lenalidomide; MPR-R , melphalan, prednisone, and lenalidomide, with lenalidomide maintenance; MPT , melphalan, prednisone, and thalidomide; PAD , bortezomib, doxorubicin, and dexamethasone; Rd , lenalidomide and low-dose dexamethasone; RD , lenalidomide and high-dose dexamethasone; VCD , bortezomib, cyclophosphamide, and dexamethasone; VD , bortezomib and dexamethasone; VMP , bortezomib, melphalan, and prednisone; VMPT-VT , bortezomib, melphalan, prednisone, and thalidomide, with bortezomib and thalidomide maintenance; VRd , lenalidomide, bortezomib, and low-dose dexamethasone; VRD , bortezomib, lenalidomide, and dexamethasone; VTD , bortezomib, thalidomide, and dexamethasone. a Therapies approved by the European Medicines Agency

Triplet induction regimens are expected to result in deeper responses than doublet regimens, and several studies have demonstrated the efficacy of triplet combinations including the proteasome inhibitor bortezomib (Table 1 ) [ 27 – 34 ]. In patients with NDMM, induction therapy with bortezomib, thalidomide, and dexamethasone (VTD) or with vincristine, doxorubicin, and dexamethasone (VAD) has been shown to improve response rates compared with either thalidomide and dexamethasone (TD) or bortezomib and dexamethasone (VD) [ 27 , 28 , 30 , 31 ]. A number of phase 3 trials compared the different available triplet regimens; bortezomib, doxorubicin, and dexamethasone (PAD) have demonstrated higher response rates and superior progression-free survival (PFS) and OS to VAD [ 32 ], and bortezomib, cyclophosphamide, and dexamethasone (VCD) have been shown to be non-inferior to PAD [ 33 ]. In a head-to-head comparison of VTD and VCD, VTD resulted in higher response rates than VCD [ 34 ]. Thus, three-drug combinations including at least bortezomib and dexamethasone are currently the standard of care before ASCT, with VTD and VCD as preferred regimens in Europe [ 1 ]. It is important to note that triplet regimens may be associated with toxicity issues. For example, the triplet VTD is associated with higher rates of peripheral neuropathy (PN) than the doublets TD and VD [ 27 , 35 ]. Subcutaneous administration of bortezomib has been shown to be effective and to reduce the incidence of PN compared with intravenous administration [ 36 ]. Furthermore, the duration of treatment should be considered: the toxicity associated with a triplet regimen may be acceptable for an induction regimen, which is administered for a relatively short period. Although it is important to take toxicity into consideration when deciding on the most appropriate treatment for an individual, efficacy should be prioritized where possible, such as when making treatment decisions for fit patients who are eligible for ASCT. Table 1 Key phase 3 studies of doublet and triplet regimens in transplant-eligible patients with newly diagnosed multiple myeloma Study Regimen N ORR (%) ≥VGPR (%) CR (%) Median PFS (months) Median OS (months) Cavo [ 27 ] TD 238 79 28 5 – – VTD 236 93 62 19 – – Harousseau [ 28 ] VD 223 79 38 6 36.0 NR VAD 218 63 15 1 29.7 NR Lokhorst [ 29 ] TAD 268 – 37 3 34.0 73 VAD 268 – 18 2 25.0 60 Moreau [ 30 ] VD 99 81 36 12 30.0 – VTD 100 88 49 13 26.0 – Rosinol [ 31 ] TD 127 – 15 a 14 8.2 – VTD 130 – 25 a 35 56.2 – Sonneveld [ 32 ] VAD 414 – 14 2 28 NR PAD 413 – 42 7 35 NR Mai [ 33 ] VCD 251 – 37.0 8.4 – – PAD 251 – 34.3 4.4 – – Moreau [ 34 ] VCD 169 83 56 9 – – VTD 169 92 66 13 – – ORR, VGPR, and CR refer to response to induction therapy CR , complete response; NR , not reached; ORR , overall response rate; OS , overall survival; PAD , bortezomib, doxorubicin, and dexamethasone; PFS , progression-free survival; Rd , lenalidomide and low-dose dexamethasone; TAD , thalidomide, adriamycin, and dexamethasone; TD , thalidomide and dexamethasone; VAD , vincristine, doxorubicin, and dexamethasone; VCD , bortezomib, cyclophosphamide, and dexamethasone; VD , bortezomib and dexamethasone; VGPR , very good partial response; VRd , bortezomib, lenalidomide, and low-dose dexamethasone; VTD , bortezomib, thalidomide, and dexamethasone a Proportion of patients with VGPR

While the efficacy of modern triplet combinations including the most recently approved drugs (such as carfilzomib, ixazomib, panobinostat, daratumumab, and elotuzumab) has been demonstrated in patients with relapsed and/or refractory MM(RRMM), they have not been extensively tested for first-line therapy. Nonetheless, positive results have been obtained in phase 2 trials of carfilzomib, lenalidomide, and low-dose dexamethasone (KRd) in patients with NDMM [ 37 – 39 ], as well as ixazomib, lenalidomide, and low-dose dexamethasone [ 40 ], and a phase 3 trial comparing KRd with bortezomib, lenalidomide, and low-dose dexamethasone (VRd) is in progress [ 41 ]. In addition, another clinical trial is investigating the use of therapy with either the triplets cyclophosphamide, lenalidomide, and dexamethasone (CRD) or cyclophosphamide, thalidomide, and dexamethasone (CTD) or a quadruple regimen, carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone (CCRD) [ 42 ]. Findings from the randomized phase 3 Myeloma XI trial suggest that treatment with CCRD induces a deeper response than either of the triplet regimens [ 43 , 44 ]; however, it should be noted that these data are preliminary and further research is needed to investigate fully the efficacy and safety of this approach. Another ongoing study in patients with NDMM is investigating induction therapy with VRD or VRD plus the monoclonal antibody elotuzumab, followed by maintenance therapy with lenalidomide with or without additional elotuzumab [ 45 ].

Although it was previously thought that potent combination therapy should be saved for use at relapse, it is now thought that its utilization earlier may increase the chances of obtaining a deep and durable response, resulting in improved outcomes. This is based on the hypothesis that potent treatment at an early stage may increase the likelihood of eradicating the majority of, or even all, subclones [ 46 ]. In addition, patients are more likely to have disease-related complications and comorbidities at later lines of treatment, which may impact on their ability to tolerate potent drug combinations, and so the use of the most effective combination treatments before these have developed may increase the likelihood of a sustained response [ 46 ]. Although further studies will be needed to determine the benefit of modern combination treatment regimens at early therapy lines, it is expected that these will help to improve responses and long-term outcomes.

In addition to induction therapy, consolidation and maintenance therapy may be given following ASCT. Consolidation therapy typically consists of a short period of intensive treatment with the aim of improving the depth of response after transplant [ 17 , 47 ]. VTD is the predominant regimen used, but studies investigating the value of consolidation are limited [ 17 , 47 – 49 ]. In contrast, maintenance therapy typically involves use of a more prolonged course of treatment with a lower-intensity regimen, with the aim of achieving long-term disease control [ 17 , 47 ]. Maintenance therapy with thalidomide, lenalidomide, or bortezomib has been shown to have some benefit [ 32 , 50 – 52 ]. Lenalidomide has been shown to improve OS compared with placebo or no maintenance therapy; a recent meta-analysis involving 1209 patients from three phase 3 randomized clinical trials of lenalidomide maintenance after ASCT demonstrated a significantly prolonged OS compared with controls [ 51 ]. Furthermore, the Myeloma XI study of more than 2000 patients with NDMM demonstrated that maintenance with lenalidomide was associated with a significantly longer median PFS compared with observation across all patient subgroups, including in those with high-risk disease [ 53 ]. In 2017, the use of lenalidomide maintenance therapy was approved for patients with NDMM following ASCT in Europe and the USA [ 54 , 55 ]. In a head-to-head trial comparing bortezomib-based induction and maintenance therapies (PAD induction, bortezomib maintenance) versus VAD induction and thalidomide maintenance, the bortezomib group achieved superior PFS, an effect that was maintained for up to 96 months of follow-up; OS was similar with both treatments [ 32 , 56 ]. Importantly, with prolonged bortezomib maintenance therapy for 96 months, there was no increased risk of second primary malignancies, which are an important complication for long-term survivors of MM [ 56 ]. A number of clinical trials to assess the use of newer agents (such as ixazomib, carfilzomib, elotuzumab, daratumumab, vorinostat, and panobinostat) for maintenance therapy are ongoing.

Summary

For transplant-eligible patients the goal is to achieve the deepest response and, if possible, a state of sustained minimal residual disease negativity. Consequently, use of a triplet regimen, such as VTD, VRd, or VCD, for induction prior to ASCT is recommended, providing toxicities allow. Owing to its potential to prolong PFS and OS, lenalidomide maintenance should be considered post-ASCT for all patients in whom it is tolerated. Additional clinical studies are needed to confirm the value of consolidation treatment after ASCT, as well as the use of newer therapies for maintenance [ 1 ].

Transplant-ineligible patients

While using the most effective agents is the main strategy for newly diagnosed, transplant-eligible patients, this is not always appropriate for transplant-ineligible patients, who are usually older and may be considered less fit owing to comorbidities, disability, or disease burden. As a result, regimens that are suitable for transplant-eligible patients may be associated with toxicity issues that lead to early treatment discontinuation, resulting in low efficacy and poor quality of life in transplant-ineligible patients [ 57 ]. For example, although data are preliminary, the doublet VD has been shown to be as effective as the triplets bortezomib, melphalan, and prednisone (VMP) and VTD, and is associated with reduced toxicity in transplant-ineligible patients [ 35 ]. Therapy in these patients frequently focuses on controlling symptoms and preserving vital organ function, performance status, and quality of life [ 57 ].

A number of studies have investigated the efficacy of triplet and doublet regimens in patients not eligible for ASCT (Table 2 ) [ 35 , 58 – 65 ], and there is some evidence to suggest that the use of a doublet may be more appropriate than a triplet [ 35 , 62 , 63 ]. For example, improved PFS and OS were demonstrated in a phase 3 study comparing lenalidomide and low-dose dexamethasone (Rd) with melphalan, prednisone, and thalidomide (MPT) [ 63 ]. Furthermore, a phase 3 study demonstrated that triplet lenalidomide-based regimens (melphalan, prednisone, and lenalidomide (MPR) and cyclophosphamide, prednisone, and lenalidomide (CPR)) were not associated with a significant difference in PFS compared with Rd in elderly patients with NDMM [ 62 ]. However, for some patients, sequential regimens may be suitable and the use of VMP and Rd administered in either a sequential or an alternating manner has been shown to be feasible, producing a similar outcome (in terms of 18-month PFS) to the trials of continuous regimens reported so far [ 66 ]. Furthermore, the use of reduced intensity bortezomib-based triplet regimens (VMP or VTP) followed by maintenance with a doublet regimen of VT or VP has been shown to be effective and more tolerable than higher intensity treatment in elderly patients with NDMM; notably, VMP was associated with fewer serious adverse events than VTP [ 59 ]. However, there is evidence to suggest that some patients may benefit from a triplet regimen; the phase 3 SWOG S0777 study demonstrated that induction therapy with VRd improved PFS and OS, compared with Rd, and had an acceptable risk-benefit profile in patients with NDMM without intent for immediate ASCT [ 64 ]. Interestingly, recent data from the phase 3 ALCYONE study in transplant-ineligible patients show that, compared with VMP, addition of daratumumab to VMP resulted in significantly higher rates of complete response and 18-month PFS. However, the quadruplet regimen was associated with a higher rate of grade 3 or 4 infections compared with the triplet regimen [ 65 ]. Table 2 Key phase 3 studies of doublet and triplet regimens in transplant-ineligible patients with newly diagnosed multiple myeloma Study Regimen N ORR (%) VGPR (%) CR (%) Median PFS (months) Median OS (months) Palumbo [ 58 ] MP 164 – 11 4 14.5 47.6 MPT 167 – 29 16 21.8 45.0 Mateos [ 59 ] VMP 130 80 – 20 34 NR VTP 130 81 – 28 25 NR Niesvizky [ 35 ] VD 168 73 – 3 14.7 49.8 VTD 167 80 – 4 15.4 51.5 VMP 167 70 – 4 17.3 53.1 Stewart [ 60 ] MPT-T 154 64 20 5 21.0 52.6 MPR-R 152 60 20 11 18.7 47.7 Hungria [ 61 ] TD 18 69 19 13 21.5 54.6 CTD 32 90 35 21 25.9 32.4 MPT 32 68 25 14 24.1 42.0 Magarotto [ 62 ] Rd 212 74 31 3 21.0 NR CPR 220 68 20 1 20.0 NR MPR 211 71 23 3 24.0 NR Hulin [ 63 ] Cont. Rd 535 81 27 21 26.0 58.9 Rd18 541 79 27 20 21.0 56.7 MPT 547 67 18 12 21.9 48.5 Durie [ 64 ] Rd 214 72 23 8 30.0 64.0 VRd 216 82 28 16 43.0 75.0 Mateos [ 65 ] VMP 356 74 25 24 18.1 NR DVMP 350 91 29 43 NR NR Cont. Rd , continuous lenalidomide and low-dose dexamethasone; CPR , cyclophosphamide, prednisone, and lenalidomide; CR , complete response; CTD , cyclophosphamide, thalidomide, and dexamethasone; DVMP , daratumumab, bortezomib, melphalan, and prednisone; MP , melphalan and prednisone; MPR , melphalan, prednisone, and lenalidomide; MPR-R , melphalan, prednisone, and lenalidomide with lenalidomide maintenance; MPT , melphalan, prednisone, and thalidomide; MPT-T , MPT with thalidomide maintenance; NR , not reached; ORR , overall response rate; OS , overall survival; PFS , progression-free survival; Rd , lenalidomide and low-dose dexamethasone; Rd18 , lenalidomide and low-dose dexamethasone for 72 weeks (18 cycles); TD , thalidomide and dexamethasone; VD , bortezomib and dexamethasone; VGPR , very good partial response; VMP , bortezomib, melphalan, and prednisone; VTD , bortezomib, thalidomide, and dexamethasone; VTP , bortezomib, thalidomide, and prednisone

When making treatment decisions for transplant-ineligible patients, it is important that factors such as patient age, comorbidities, degree of frailty, and patient preference are taken into account [ 17 , 57 , 67 , 68 ]. The International Myeloma Working Group (IMWG) recently developed a scoring system based on age, comorbidities, and cognitive and physical condition to classify patients in “fit,” “intermediate-fit”, and “frail” groups [ 67 , 68 ]. Management strategies can then be tailored accordingly (Fig. 1 ). For example, regimens consisting of two or three drugs at full dose may be appropriate for patients defined as fit, while those defined as intermediate-fit may be treated with two (or three) drugs at a reduced dose, and those defined as frail with one or two drugs at a significantly reduced dose [ 17 , 57 ]. In particular, CTD, MPT, CRD, Rd, VRd, or VMP may be suitable for fit or intermediate-fit patients [ 61 , 69 – 71 ], while MP or cyclophosphamide and dexamethasone (CD) may be more appropriate for intermediate-fit or frail patients.

Summary

Many transplant-ineligible patients, and particularly those who are frail, are unlikely to tolerate aggressive combinations. Instead, a more conservative approach employing the use of reduced intensity combination or sequential treatments, that takes into consideration possible toxicity issues and likely tolerability, may be more appropriate in this group of patients. However, it is important to assess the fitness of transplant-ineligible patients because those who are ‘fit’ may be able to benefit from two- or three-drug regimens used at full dose.

Management of patients with relapsed/refractory multiple myeloma

Relapse of MM is considered to be almost inevitable and the management of patients with RRMM requires an individualized approach. This should take into account the patient’s age, fitness, comorbidities, treatment history (including both depth and duration of the response, as well as treatment toxicities), and aggressiveness of the relapse, as well as the expectations of the patient and his or her quality of life [ 17 , 72 , 73 ]. Treatment options include re-treating with an agent used previously, switching to a different agent in the same drug class, or switching to an agent in a different drug class (Fig. 2 ). ASCT may be considered as a salvage option if patients are transplant-eligible and have either never received an ASCT or had a previous ASCT with a long response duration [ 73 – 77 ]. Patients should also be considered for participation in clinical trials, if available [ 17 , 72 , 73 , 78 ]. Fig. 2 Treatment algorithm for patients with relapsed/refractory multiple myeloma. ASCT , autologous stem cell transplantation; CRD , cyclophosphamide, lenalidomide, and dexamethasone; CTD , cyclophosphamide, thalidomide, and dexamethasone; IMiD , immunomodulatory drug; IxRd , ixazomib, lenalidomide, and low-dose dexamethasone; Kd , carfilzomib and low-dose dexamethasone; KRd , carfilzomib, lenalidomide, and low-dose dexamethasone; MM , multiple myeloma; MPT , melphalan, prednisone, and thalidomide; PAD , bortezomib, doxorubicin, and dexamethasone; PanVD , panobinostat, bortezomib, and dexamethasone; PomD , pomalidomide and dexamethasone; Rd , lenalidomide and low-dose dexamethasone; RD , lenalidomide and high-dose dexamethasone; TD , thalidomide and dexamethasone; TFI , treatment-free interval; VCD , bortezomib, cyclophosphamide, and dexamethasone; V ± D , bortezomib with or without dexamethasone; VMP , bortezomib, melphalan, and prednisone; V/PLD , bortezomib and pegylated liposomal doxorubicin; VRD , bortezomib, lenalidomide, and dexamethasone; VTD , bortezomib, thalidomide, and dexamethasone. a Therapies approved by the European Medicines Agency

In general, doublet or triplet regimens are used in RRMM (Table 3 ) [ 7 – 10 , 14 – 16 , 79 , 80 ], with the specific treatment choice dependent upon the expected efficacy, toxicity, and possible cost considerations, as well as the fitness of the patient [ 17 , 72 , 78 ]. Bortezomib, thalidomide, and lenalidomide were frequently used for the treatment of RRMM [ 17 , 72 , 73 ]. For example, combinations such as VTD, VRD, VCD, and bortezomib with doxorubicin and dexamethasone (PAD) may still be considered; in particular, the triplet VTD has been shown to be superior to TD in patients with relapsed disease post ASCT [ 17 , 79 ]. However, the presence of comorbidities such as PN may mean that changes are made to the dose or schedule, or necessitate use of an alternative drug class [ 72 , 78 , 81 ]. Rd is also an effective option [ 72 , 82 , 83 ] and TD may be appropriate, especially if patients are thalidomide-naïve or are not eligible for bortezomib or lenalidomide-based treatment [ 72 ]. Table 3 Key phase 3 studies of doublet and triplet regimens in patients with relapsed and/or refractory multiple myeloma Study Regimen N ORR (%) VGPR (%) CR (%) Median PFS (months) Median OS (months) Garderet [ 79 ] TD 134 72 14 13 13.6 – VTD 135 87 11 28 18.3 – San-Miguel [ 14 ] VD 381 55 – 6 8.1 30.4 PanVD 387 61 – 11 12.0 33.6 Baz [ 80 ] PomD 36 39 – – 4.4 10.5 PCD 34 65 – – 9.2 16.4 Stewart [ 7 ] Rd 396 67 40 5 17.6 NR KRd 396 87 70 18 26.3 NR Lonial [ 9 ] Rd 325 66 21 7 14.9 NR Rd + elotuzumab 321 79 28 4 19.4 NR Moreau [ 10 ] Rd 362 72 32 7 14.7 NR IxRd 360 78 36 12 20.6 NR Palumbo [ 15 ] Vd 247 63 20 7 7.2 – Vd + daratumumab 251 83 40 15 NR – Dimopoulos [ 4 , 8 ] Kd 464 77 42 13 18.7 47.6 Vd 465 63 22 6 9.4 40.0 Dimopoulos [ 16 ] Rd 283 76 25 19 18.4 – Rd + daratumumab 286 93 33 43 NR – CR , complete response; IxRd , ixazomib, lenalidomide, and low-dose dexamethasone; Kd , carfilzomib and low-dose dexamethasone; KRd , carfilzomib, lenalidomide, and low-dose dexamethasone; NR , not reached; ORR , overall response rate; OS , overall survival; PanVD , panobinostat, bortezomib, and dexamethasone; PCD , pomalidomide, cyclophosphamide, and dexamethasone; PFS , progression-free survival; PomD , pomalidomide and dexamethasone; Rd , lenalidomide and low-dose dexamethasone; TD , thalidomide and dexamethasone; Vd , bortezomib and low-dose dexamethasone; VD , bortezomib and dexamethasone; VGPR , very good partial response; VTD , bortezomib, thalidomide, and dexamethasone

The development of novel agents for the treatment of MM has significantly increased the range of possible treatment combinations and these may result in even better outcomes for patients with RRMM. KRd has been shown to have a significant impact on PFS and OS, with a favorable risk–benefit profile and improved health-related quality of life compared with Rd [ 7 , 84 ]. The benefit of this regimen in terms of PFS was observed in all patients, including those who had previously received treatment with bortezomib or lenalidomide or who had high-risk cytogenetics. The combination of carfilzomib with low-dose dexamethasone (Kd) has also been shown to result in improved PFS and OS compared with bortezomib combined with low-dose dexamethasone (Vd) [ 4 , 8 ]. PN has been shown to be less frequent in patients treated with carfilzomib than in those receiving bortezomib, and addition of carfilzomib to Rd did not add PN toxicity, so carfilzomib regimens may be a suitable option for patients including those with existing or anticipated neuropathy [ 8 , 78 ].

Another second-generation proteasome inhibitor, ixazomib, has been developed, and the combination of ixazomib with lenalidomide and low-dose dexamethasone has been shown to result in improved PFS compared with placebo, lenalidomide, and low-dose dexamethasone in patients with RRMM [ 10 ]. Ixazomib is available in the USA and received approval for use in Europe in December 2016 [ 10 , 85 ]. In addition, the availability of the immunomodulatory agent pomalidomide and the HDAC inhibitor panobinostat has opened up the possibility of using doublet or triplet regimens in patients with advanced disease [ 11 , 12 , 14 ]. In particular, pomalidomide in combination with dexamethasone is suitable for use in patients who have received at least two previous treatment regimens and have demonstrated disease progression [ 12 , 86 ]. Studies investigating the use of pomalidomide, bortezomib, and dexamethasone (PVd), pomalidomide, cyclophosphamide, and prednisone (PCP), pomalidomide, cyclophosphamide, and dexamethasone (PCD) and pomalidomide, carfilzomib, and dexamethasone (PKD), also suggest that these regimens may be effective in RRMM [ 11 , 80 , 87 , 88 ]. Additionally, although not currently approved in the relapsed setting, the alkylating agent bendamustine in combination with thalidomide and dexamethasone has been shown to be a viable salvage therapy for patients with relapsed disease who are refractory to bortezomib and lenalidomide [ 13 ].

The use of monoclonal antibodies is well established for the treatment of other cancers and although these agents have only recently become available for the treatment of RRMM, they are already showing promise. The anti-CD38 monoclonal antibody daratumumab has been shown to be effective in patients with RRMM in a number of studies, either as monotherapy or in combination with lenalidomide and dexamethasone [ 89 , 90 ]. In addition, results from a phase 3 trial of daratumumab with bortezomib and dexamethasone (CASTOR) demonstrated a significant improvement in PFS compared with bortezomib and dexamethasone alone [ 15 ]; PFS was also found to be improved in patients treated with daratumumab, lenalidomide, and dexamethasone versus those who received lenalidomide and dexamethasone only (POLLUX) [ 16 ]. In addition, the anti-SLAM-7 antibody elotuzumab combined with lenalidomide and dexamethasone was associated with improved PFS in patients with RRMM compared with lenalidomide and dexamethasone alone [ 9 ]. Results from a phase 2 study also indicate improved PFS in patients treated with elotuzumab, bortezomib, and dexamethasone versus those treated with bortezomib and dexamethasone alone [ 91 ]. These findings suggest that monoclonal antibodies will have an important role in the future treatment of patients with RRMM, and several ongoing trials are assessing their value when combined with other therapeutic agents [ 92 – 95 ].

When making treatment decisions, the prognosis may influence the therapeutic strategy chosen. For example, recent recommendations from the IMWG suggest that patients with a poor prognosis at relapse are treated with a triplet or quadruplet regimen, until disease progression [ 73 ]. In this setting, novel treatments may be more appropriate than bortezomib or alkylating agents, because these agents are suitable for use until disease progression [ 54 , 85 , 96 , 97 ]. In contrast, it is recommended that patients with indolent disease characteristics are treated with one- or two-drug regimens and treatment-free intervals may be appropriate for these individuals [ 73 ]. In addition, existing comorbidities may make it necessary to consider dose adjustments, for example reduced doses of ixazomib and lenalidomide are recommended for patients with severe renal impairment [ 54 , 85 ].

The response to previous therapies must also be taken into account when making treatment decisions. Re-treatment with a drug used previously should be feasible, provided that a clinically meaningful response was achieved, the previous response lasted for at least 12 months, and treatment was associated with acceptable toxicity [ 17 , 72 , 78 ]. In patients who demonstrate disease progression while on therapy, or who had only a short response, switching to a different drug class should be considered [ 73 ]. For example, if lenalidomide was used as first-line treatment, bortezomib could be used at relapse. Alternatively, it may be possible to use a second-generation agent in the same drug class as the treatment used at first line. For example, carfilzomib is structurally and mechanistically distinct from bortezomib and has been shown to be effective in patients who previously received bortezomib [ 7 , 8 ]. In addition, studies have demonstrated that pomalidomide is effective in patients for whom lenalidomide has failed [ 98 ], as well as in those who are refractory to both lenalidomide and bortezomib [ 12 , 99 ]. Given the number of novel agents now available in both existing and new drug classes, it should be possible for patients to receive treatment at relapse with an agent that they are not resistant to, even if they receive a combination treatment initially. However, long-term data on the use of the newest agents following different initial treatment combinations are limited and so further studies will be needed to determine whether particular sequences of drug regimens are associated with improved responses and long-term outcomes.

Summary

In the relapse setting, triplet regimens including lenalidomide, dexamethasone, and either a monoclonal antibody or a proteasome inhibitor are recommended, although this may depend on the therapies employed at first line. If a bortezomib-based regimen was used at first line, a lenalidomide-based regimen can be used at relapse and vice versa. Regimens employing the next-generation immunomodulatory drug pomalidomide are currently under investigation and are likely to prove useful for patients with RRMM [ 100 , 101 ].

Considerations for patients with standard-risk versus high-risk disease

Although response to treatment and survival of patients with MM is highly variable, there are certain prognostic factors that can be used to predict the clinical course of the disease [ 1 ]. Patients can be stratified into high-risk and standard-risk disease groups according to the presence or absence of various disease characteristics such as cytogenetic abnormalities, elevated serum β2-microglobulin levels, and elevated serum lactate dehydrogenase levels (Table 4 ) [ 73 , 102 – 104 ]. Treatment decisions can then be made on the basis of these risk classifications. Table 4 High-risk disease characteristics in multiple myeloma [ 73 , 102 – 104 ] R-ISS stage • R-ISS III - serum β2-microglobulin level > 5.5 mg/L and either high-risk chromosomal abnormalities [del(17p) and/or t(4;14) and/or t(14;16)] or high serum LDH (> upper limit of normal) Host characteristics • Advanced age • Low performance status • Increased comorbidities Disease characteristics • Presence of extramedullary disease • Aggressive clinical features, including: - Rapid onset of clinical symptoms - Extensive disease at relapse (based on laboratory, pathology, or radiographic findings) - Disease-associated organ dysfunction at relapse (including renal failure, hypercalcemia, cytopenias, or bone event such as fracture) • Circulating plasma cells • Reduced polyclonal bone marrow plasma cells • High serum free light chain LDH , lactate dehydrogenase; R-ISS , revised International Staging System

In general, patients with high-risk disease (including high-risk cytogenetics and/or high tumor load) should be treated with a triplet regimen, if possible. Trials studying the use of thalidomide during induction therapy in transplant-eligible patients with NDMM indicate that this therapy does not overcome the adverse prognosis associated with high-risk cytogenetics [ 26 , 31 , 103 , 105 ]. However, patients with t(4;14) may benefit from a proteasome inhibitor-based treatment, and the combination of a proteasome inhibitor with lenalidomide and dexamethasone has been recommended by the IMWG for newly diagnosed transplant-eligible patients with high-risk cytogenetics [ 103 , 106 ]. Results from a recent post hoc analysis suggest that cytogenetic risk should also be taken into account in the context of sequential therapy. While PFS at second line (PFS2) was not influenced by treatment sequence in patients with standard-risk cytogenetics, PFS2 was reduced in individuals with high-risk cytogenetics who received lenalidomide upfront followed by bortezomib at first relapse, compared with those who received the same treatment at relapse or who received bortezomib upfront [ 107 ]. In addition, double high-dose therapy/ASCT combined with bortezomib may improve PFS in patients with high-risk cytogenetics (t(4;14) or del(17p)) [ 103 ].

In patients with RRMM and high-risk disease, doublet therapy consisting of pomalidomide plus low-dose dexamethasone may be a suitable option [ 73 , 108 ]; in particular, this therapy option has been shown to be active in patients with del(17p) [ 109 ]. The phase 3 trials of KRd and Kd in patients with RRMM suggest that carfilzomib is also effective in patients with high-risk cytogenetics [ 7 , 8 , 110 ]. Similarly, subgroup analysis of the phase 3 TOURMALINE-MM1 trial of ixazomib plus Rd suggest that this combination is effective in patients with high-risk cytogenetics [ 40 ]. Additionally, recent subgroup analyses of the phase 3 POLLUX and CASTOR trials suggest that, compared with control treatment, daratumumab improves response rates and PFS in patients with high-risk disease and in those with standard-risk disease [ 111 , 112 ]. One other option for high-risk patients with relapsed MM is allogeneic stem cell transplantation. However, this is suitable only for a subset of patients who are young and who have an available human leukocyte antigen-matched donor, chemotherapy-sensitive disease, and an excellent performance status, and it should ideally be performed in the context of a clinical trial [ 73 ].

Summary

The treatment of patients with high-risk disease with a triplet regimen including a proteasome inhibitor and an immunomodulatory drug is recommended. A triplet regimen, perhaps including the novel immunomodulatory drug pomalidomide or a proteasome inhibitor such as carfilzomib, may be an option for patients with RRMM and high-risk disease.

Future treatment strategies

Multiple myeloma should not be considered to be one disease, but rather a mix of different disease entities that further interact with individual patient characteristics [ 102 ]. Risk stratification is crucial to identify patients with a high risk of early relapse in order to adapt treatment regimens accordingly; however, further work is required to develop tools that take into account the broad spectrum of factors that define risk, both in the front-line and relapsed settings [ 102 , 113 ]. Beyond risk stratification, the advent of various high-throughput technologies in myeloma cell genotyping and phenotyping are bringing personalized myeloma therapy ever closer. Gene expression profiling of malignant plasma cells is a promising method for prognostication and may inform treatment choices [ 114 – 116 ]. For example, the presence of NRAS mutations has been shown to be associated with poor response to bortezomib [ 117 ]. Conversely, mutations in IRF4 are associated with favorable outcomes following immunomodulatory agent therapy [ 118 ]. Finally, the identification of novel mutations may lead to the development of new targeted therapies in myeloma [ 118 ]. For example, overexpression of BCL-2 has been implicated in the growth of t(11;14) myeloma cells and preliminary results from a phase 1 study suggest that the BCL-2 inhibitor venetoclax may be effective in treating patients with t(11;14) [ 119 ].

Given the array of therapeutic options available and the efficacy of triplet regimens, it might be expected that use of quadruplet regimens would result in even better outcomes. The efficacy and safety of quadruplet regimens have been investigated in a limited number of studies; although preliminary data suggest that the quadruplet CCRD is effective [ 43 ], studies of other quadruplet regimens have reported toxicity issues [ 120 ]. Further studies will be needed to assess the value of these regimens. A number of phase 3 studies assessing the value of quadruplet regimens including a monoclonal antibody are ongoing [ 121 , 122 ].

Other new therapeutic agents are under investigation, including novel proteasome inhibitors (oprozomib and marizomib), HDAC inhibitors (romidepsin, vorinostat, ricolinostat), monoclonal antibodies (SAR650984, MOR202, isatuximab, ipilimumab), and small-molecule inhibitors (vemurafenib, venetoclax, CPI-0610, LGH447, dinaciclib, selinexor, ibrutinib, and filanesib) [ 6 , 23 , 95 , 123 ]. The efficacy of these remains to be fully tested; however, they should help to expand the range of therapeutic options available. This is particularly important because the use of combination therapies at first line increases the risk of developing resistance to multiple classes of drug, necessitating the use of different agents at later lines. In addition, the use of existing therapies has already been shown to be associated with high costs [ 124 ], and it is likely that novel agents will increase these further, placing a significant burden on healthcare providers and funding bodies. As more novel agents emerge, cost-effectiveness analyses will be needed to establish the value of adopting combination regimens. Nonetheless, it seems probable that the development of new treatments is likely to result in improvements in the long-term management of patients with MM and raises the possibility that in the future it may be possible to cure the disease, particularly in patients who are able to tolerate combination therapy with a range of different agents.

Conclusions

The treatment landscape for MM has evolved significantly over the past decade, and several therapeutic options are now available. In particular, the development and availability of monoclonal antibodies may well lead to a treatment paradigm shift whereby the use of a monoclonal antibody in combination with a doublet or triplet regimen may be suitable for treatment of the disease. Of course, the heterogeneity of MM means that an individualized approach is still required when making treatment decisions. This should involve risk stratification and the assessment of the patient’s frailty, disabilities, and comorbidities and, in the RRMM setting, consideration of previous treatment history and response.

The availability of novel agents makes combinations of drugs from different classes possible, and the latest results from clinical studies suggest that the efficacy benefits of treatment combinations involving these agents are likely to outweigh the risk of patients developing multi-drug resistance. However, it remains important for physicians to consider the aims of treatment carefully, and to ensure that there is an appropriate balance between response and toxicity. There is also a need to investigate novel treatment combinations and sequences further, with the aim of achieving greater responses while minimizing treatment-related toxicity, as well as the potential benefits of treating patients with high-risk smoldering MM. Additional work in these areas should ultimately lead to improved treatment regimens and outcomes for patients with MM.

Acknowledgements

The authors would like to thank Laura Pearce, PhD, from Oxford PharmaGenesis, Oxford, UK, who provided medical writing support and Emma Booth and Sarah Petrig from Amgen (Europe) GmbH for their editorial support. Medical writing support was funded by Amgen (Europe) GmbH.

Authors’ contributions

HG made a substantial contribution to conception of the article, was involved with developing the draft of the article and revising it critically for important intellectual content, approved the final manuscript as submitted, and agrees to be accountable for all aspects of the work. JA made a substantial contribution to conception of the article, was involved with developing the draft of the article and revising it critically for important intellectual content, approved the final manuscript as submitted, and agrees to be accountable for all aspects of the work. ZS made a substantial contribution to conception of the article, was involved with developing the draft of the article and revising it critically for important intellectual content, approved the final manuscript as submitted, and agrees to be accountable for all aspects of the work. LG made a substantial contribution to conception of the article, was involved with developing the draft of the article and revising it critically for important intellectual content, approved the final manuscript as submitted, and agrees to be accountable for all aspects of the work.

Compliance with ethical standards

Conflict of interest

HG has received research support from Bristol-Myers Squibb, Celgene Ltd., Chugai, Janssen, Millenium Pharmaceuticals, Inc., and Novartis International AG, has participated in advisory boards for Amgen, Bristol-Myers Squibb, Celgene Ltd., Janssen, Novartis International AG, Onyx Pharmaceuticals, Inc., and Takeda, and has received honoraria from Celgene Ltd., Chugai, Janssen, Millenium Pharmaceuticals, Inc., Novartis International AG, and Onyx Pharmaceuticals, Inc. JA has participated in advisory boards and as a consultant for Amgen, Celgene Ltd., Janssen, and Takeda. ZS is an employee of Amgen and holds stock. LG is a consultant for Amgen, Novartis International AG, and Takeda.

References

1. Moreau P San Miguel J Sonneveld P Mateos MV Zamagni E Avet-Loiseau H Hajek R Dimopoulos MA Ludwig H Einsele H Zweegman S Facon T Cavo M Terpos E Goldschmidt H Attal M Buske C Committee EG Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 2017 28 iv52 iv61 10.1093/annonc/mdx096 28453614

2. Kumar SK Rajkumar SV Dispenzieri A Lacy MQ Hayman SR Buadi FK Zeldenrust SR Dingli D Russell SJ Lust JA Greipp PR Kyle RA Gertz MA Improved survival in multiple myeloma and the impact of novel therapies Blood 2008 111 5 2516 2520 10.1182/blood-2007-10-116129 17975015 PMC2254544

3. Kumar SK Dispenzieri A Lacy MQ Gertz MA Buadi FK Pandey S Kapoor P Dingli D Hayman SR Leung N Lust J McCurdy A Russell SJ Zeldenrust SR Kyle RA Rajkumar SV Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients Leukemia 2014 28 5 1122 1128 10.1038/leu.2013.313 24157580 PMC4000285

4. Dimopoulos MA Goldschmidt H Niesvizky R Joshua D Chng WJ Oriol A Orlowski RZ Ludwig H Facon T Hajek R Weisel K Hungria V Minuk L Feng S Zahlten-Kumeli A Kimball AS Moreau P Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial Lancet Oncol 2017 18 10 1327 1337 10.1016/S1470-2045(17)30578-8 28843768

5. Larsen JT Kumar S Evolving paradigms in the management of multiple myeloma: novel agents and targeted therapies Rare Cancers Ther 2015 3 47 68 10.1007/s40487-015-0009-4 27182478 PMC4837942

6. Ocio EM Richardson PG Rajkumar SV Palumbo A Mateos MV Orlowski R Kumar S Usmani S Roodman D Niesvizky R Einsele H Anderson KC Dimopoulos MA Avet-Loiseau H Mellqvist UH Turesson I Merlini G Schots R McCarthy P Bergsagel L Chim CS Lahuerta JJ Shah J Reiman A Mikhael J Zweegman S Lonial S Comenzo R Chng WJ Moreau P Sonneveld P Ludwig H Durie BG Miguel JF New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG) Leukemia 2014 28 3 525 542 10.1038/leu.2013.350 24253022 PMC4143389

7. Stewart AK Rajkumar SV Dimopoulos MA Masszi T Spicka I Oriol A Hajek R Rosinol L Siegel DS Mihaylov GG Goranova-Marinova V Rajnics P Suvorov A Niesvizky R Jakubowiak AJ San-Miguel JF Ludwig H Wang M Maisnar V Minarik J Bensinger WI Mateos MV Ben-Yehuda D Kukreti V Zojwalla N Tonda ME Yang X Xing B Moreau P Palumbo A Investigators A Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma N Engl J Med 2015 372 2 142 152 10.1056/NEJMoa1411321 25482145

8. Dimopoulos MA Moreau P Palumbo A Joshua D Pour L Hajek R Facon T Ludwig H Oriol A Goldschmidt H Rosinol L Straub J Suvorov A Araujo C Rimashevskaya E Pika T Gaidano G Weisel K Goranova-Marinova V Schwarer A Minuk L Masszi T Karamanesht I Offidani M Hungria V Spencer A Orlowski RZ Gillenwater HH Mohamed N Feng S Chng WJ Investigators E Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study Lancet Oncol 2016 17 1 27 38 10.1016/S1470-2045(15)00464-7 26671818

9. Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Rollig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P, Eloquent Investigators (2015) Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 373(7):621–631. 10.1056/NEJMoa1505654 10.1056/NEJMoa1505654 26035255

10. Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG, Tourmaline-MM Study Group (2016) Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374(17):1621–1634. 10.1056/NEJMoa1516282 10.1056/NEJMoa1516282 27119237

11. Larocca A Montefusco V Bringhen S Rossi D Crippa C Mina R Galli M Marcatti M La Verde G Giuliani N Magarotto V Guglielmelli T Rota-Scalabrini D Omede P Santagostino A Baldi I Carella AM Boccadoro M Corradini P Palumbo A Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study Blood 2013 122 16 2799 2806 10.1182/blood-2013-03-488676 23954889

12. San Miguel J Weisel K Moreau P Lacy M Song K Delforge M Karlin L Goldschmidt H Banos A Oriol A Alegre A Chen C Cavo M Garderet L Ivanova V Martinez-Lopez J Belch A Palumbo A Schey S Sonneveld P Yu X Sternas L Jacques C Zaki M Dimopoulos M Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial Lancet Oncol 2013 14 11 1055 1066 10.1016/S1470-2045(13)70380-2 24007748

13. Lau IJ Smith D Aitchison R Blesing N Roberts P Peniket A Yong K Rabin N Ramasamy K Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide Ann Hematol 2015 94 4 643 649 10.1007/s00277-014-2238-2 25345871

14. San-Miguel JF Hungria VT Yoon SS Beksac M Dimopoulos MA Elghandour A Jedrzejczak WW Gunther A Nakorn TN Siritanaratkul N Corradini P Chuncharunee S Lee JJ Schlossman RL Shelekhova T Yong K Tan D Numbenjapon T Cavenagh JD Hou J LeBlanc R Nahi H Qiu L Salwender H Pulini S Moreau P Warzocha K White D Blade J Chen W de la Rubia J Gimsing P Lonial S Kaufman JL Ocio EM Veskovski L Sohn SK Wang MC Lee JH Einsele H Sopala M Corrado C Bengoudifa BR Binlich F Richardson PG Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial Lancet Oncol 2014 15 11 1195 1206 10.1016/S1470-2045(14)70440-1 25242045

15. Palumbo A Chanan-Khan A Weisel K Nooka AK Masszi T Beksac M Spicka I Hungria V Munder M Mateos MV Mark TM Qi M Schecter J Amin H Qin X Deraedt W Ahmadi T Spencer A Sonneveld P Investigators C Daratumumab, bortezomib, and dexamethasone for multiple myeloma N Engl J Med 2016 375 8 754 766 10.1056/NEJMoa1606038 27557302

16. Dimopoulos MA Oriol A Nahi H San-Miguel J Bahlis NJ Usmani SZ Rabin N Orlowski RZ Komarnicki M Suzuki K Plesner T Yoon SS Ben Yehuda D Richardson PG Goldschmidt H Reece D Lisby S Khokhar NZ O'Rourke L Chiu C Qin X Guckert M Ahmadi T Moreau P Investigators P Daratumumab, lenalidomide, and dexamethasone for multiple myeloma N Engl J Med 2016 375 14 1319 1331 10.1056/NEJMoa1607751 27705267

17. Ludwig H Sonneveld P Davies F Blade J Boccadoro M Cavo M Morgan G de la Rubia J Delforge M Dimopoulos M Einsele H Facon T Goldschmidt H Moreau P Nahi H Plesner T San-Miguel J Hajek R Sondergeld P Palumbo A European perspective on multiple myeloma treatment strategies in 2014 Oncologist 2014 19 8 829 844 10.1634/theoncologist.2014-0042 25063227 PMC4122482

18. Nooka A Lonial S Sequential or combination therapy for multiple myeloma Expert Rev Hematol 2012 5 5 533 545 10.1586/ehm.12.49 23146057

19. Keats JJ Chesi M Egan JB Garbitt VM Palmer SE Braggio E Van Wier S Blackburn PR Baker AS Dispenzieri A Kumar S Rajkumar SV Carpten JD Barrett M Fonseca R Stewart AK Bergsagel PL Clonal competition with alternating dominance in multiple myeloma Blood 2012 120 5 1067 1076 10.1182/blood-2012-01-405985 22498740 PMC3412330

20. Altun M Galardy PJ Shringarpure R Hideshima T LeBlanc R Anderson KC Ploegh HL Kessler BM Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells Cancer Res 2005 65 17 7896 7901 10.1158/0008-5472.CAN-05-0506 16140960

21. Anderson KC The 39th David A. Karnofsky lecture: bench-to-bedside translation of targeted therapies in multiple myeloma J Clin Oncol 2012 30 4 445 452 10.1200/JCO.2011.37.8919 22215754 PMC4800820

22. van de Donk NW Janmaat ML Mutis T Lammerts van Bueren JJ Ahmadi T Sasser AK Lokhorst HM Parren PW Monoclonal antibodies targeting CD38 in hematological malignancies and beyond Immunol Rev 2016 270 1 95 112 10.1111/imr.12389 26864107 PMC4755228

23. Cornell RF Kassim AA Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity Bone Marrow Transplant 2016 51 4 479 491 10.1038/bmt.2015.307 26726946 PMC4827007

24. Engelhardt M Terpos E Kleber M Gay F Wasch R Morgan G Cavo M van de Donk N Beilhack A Bruno B Johnsen HE Hajek R Driessen C Ludwig H Beksac M Boccadoro M Straka C Brighen S Gramatzki M Larocca A Lokhorst H Magarotto V Morabito F Dimopoulos MA Einsele H Sonneveld P Palumbo A European Myeloma N European myeloma network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma Haematologica 2014 99 2 232 242 10.3324/haematol.2013.099358 24497560 PMC3912952

25. Palumbo A Gay F Bringhen S Falcone A Pescosta N Callea V Caravita T Morabito F Magarotto V Ruggeri M Avonto I Musto P Cascavilla N Bruno B Boccadoro M Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma Ann Oncol 2008 19 6 1160 1165 10.1093/annonc/mdn018 18326520

26. Morgan GJ, Davies FE, Gregory WM, Russell NH, Bell SE, Szubert AJ, Navarro Coy N, Cook G, Feyler S, Byrne JL, Roddie H, Rudin C, Drayson MT, Owen RG, Ross FM, Jackson GH, Child JA, NCRI Haematological Oncology Study Group (2011) Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood 118(5):1231–1238. 10.1182/blood-2011-02-338665 10.1182/blood-2011-02-338665 PMC3152492 21652683

27. Cavo M Tacchetti P Patriarca F Petrucci MT Pantani L Galli M Di Raimondo F Crippa C Zamagni E Palumbo A Offidani M Corradini P Narni F Spadano A Pescosta N Deliliers GL Ledda A Cellini C Caravita T Tosi P Baccarani M Network GIM Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study Lancet 2010 376 9758 2075 2085 10.1016/S0140-6736(10)61424-9 21146205

28. Harousseau JL Attal M Avet-Loiseau H Marit G Caillot D Mohty M Lenain P Hulin C Facon T Casassus P Michallet M Maisonneuve H Benboubker L Maloisel F Petillon MO Webb I Mathiot C Moreau P Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial J Clin Oncol 2010 28 30 4621 4629 10.1200/JCO.2009.27.9158 20823406

29. Lokhorst HM van der Holt B Zweegman S Vellenga E Croockewit S van Oers MH von dem Borne P Wijermans P Schaafsma R de Weerdt O Wittebol S Delforge M Berenschot H Bos GM Jie KS Sinnige H van Marwijk-Kooy M Joosten P Minnema MC van Ammerlaan R Sonneveld P Dutch-Belgian Hemato-Oncology G A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma Blood 2010 115 6 1113 1120 10.1182/blood-2009-05-222539 19880501

30. Moreau P Avet-Loiseau H Facon T Attal M Tiab M Hulin C Doyen C Garderet L Randriamalala E Araujo C Lepeu G Marit G Caillot D Escoffre M Lioure B Benboubker L Pegourie B Kolb B Stoppa AM Fuzibet JG Decaux O Dib M Berthou C Chaleteix C Sebban C Traulle C Fontan J Wetterwald M Lenain P Mathiot C Harousseau JL Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma Blood 2011 118 22 5752 5758 10.1182/blood-2011-05-355081 21849487

31. Rosinol L, Oriol A, Teruel AI, Hernandez D, Lopez-Jimenez J, de la Rubia J, Granell M, Besalduch J, Palomera L, Gonzalez Y, Etxebeste MA, Diaz-Mediavilla J, Hernandez MT, de Arriba F, Gutierrez NC, Martin-Ramos ML, Cibeira MT, Mateos MV, Martinez J, Alegre A, Lahuerta JJ, San Miguel J, Blade J, Programa para el Estudio y la Terapeutica de las Hemopatias Malignas/Grupo Espanol de Mieloma g (2012) Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 120(8):1589–1596. 10.1182/blood-2012-02-408922 10.1182/blood-2012-02-408922 22791289

32. Sonneveld P Schmidt-Wolf IG van der Holt B El Jarari L Bertsch U Salwender H Zweegman S Vellenga E Broyl A Blau IW Weisel KC Wittebol S Bos GM Stevens-Kroef M Scheid C Pfreundschuh M Hose D Jauch A van der Velde H Raymakers R Schaafsma MR Kersten MJ van Marwijk-Kooy M Duehrsen U Lindemann W Wijermans PW Lokhorst HM Goldschmidt HM Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial J Clin Oncol 2012 30 24 2946 2955 10.1200/JCO.2011.39.6820 22802322

33. Mai EK Bertsch U Durig J Kunz C Haenel M Blau IW Munder M Jauch A Schurich B Hielscher T Merz M Huegle-Doerr B Seckinger A Hose D Hillengass J Raab MS Neben K Lindemann HW Zeis M Gerecke C Schmidt-Wolf IG Weisel K Scheid C Salwender H Goldschmidt H Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma Leukemia 2015 29 8 1721 1729 10.1038/leu.2015.80 25787915

34. Moreau P Hulin C Macro M Caillot D Chaleteix C Roussel M Garderet L Royer B Brechignac S Tiab M Puyade M Escoffre M Stoppa AM Facon T Pegourie B Chaoui D Jaccard A Slama B Marit G Laribi K Godmer P Luycx O Eisenmann JC Allangba O Dib M Araujo C Fontan J Belhadj K Wetterwald M Dorvaux V Fermand JP Rodon P Kolb B Glaisner S Malfuson JV Lenain P Biron L Planche L Caillon H Avet-Loiseau H Dejoie T Attal M VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial Blood 2016 127 21 2569 2574 10.1182/blood-2016-01-693580 27002117

35. Niesvizky R Flinn IW Rifkin R Gabrail N Charu V Clowney B Essell J Gaffar Y Warr T Neuwirth R Zhu Y Elliott J Esseltine DL Niculescu L Reeves J Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens J Clin Oncol 2015 33 33 3921 3929 10.1200/JCO.2014.58.7618 26056177

36. Mateos M-V, San Miguel JF (2012) Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma. Ther Adv Hematol 3(2):117–124. 10.1177/2040620711432020 10.1177/2040620711432020 PMC3573435 23556118

37. Jakubowiak AJ Dytfeld D Griffith KA Lebovic D Vesole DH Jagannath S Al-Zoubi A Anderson T Nordgren B Detweiler-Short K Stockerl-Goldstein K Ahmed A Jobkar T Durecki DE McDonnell K Mietzel M Couriel D Kaminski M Vij R A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma Blood 2012 120 9 1801 1809 10.1182/blood-2012-04-422683 22665938 PMC5162553

38. Korde N Roschewski M Zingone A Kwok M Manasanch EE Bhutani M Tageja N Kazandjian D Mailankody S Wu P Morrison C Costello R Zhang Y Burton D Mulquin M Zuchlinski D Lamping L Carpenter A Wall Y Carter G Cunningham SC Gounden V Sissung TM Peer C Maric I Calvo KR Braylan R Yuan C Stetler-Stevenson M Arthur DC Kong KA Weng L Faham M Lindenberg L Kurdziel K Choyke P Steinberg SM Figg W Landgren O Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma JAMA Oncol 2015 1 6 746 754 10.1001/jamaoncol.2015.2010 26181891 PMC6662597

39. Roussel M, Lauwers-Cances V, Robillard N, Belhadj K, Facon T, Garderet L, Escoffre M, Pegourie B, Benboubker L, Caillot D, Fohrer C, Moreau P, Leleu X, Avet-Loiseau H, Attal M (2016) Frontline therapy with carfilzomib, lenalidomide, and dexamethasone (KRd) induction followed by autologous stem cell transplantation, KRd consolidation and lenalidomide maintenance in newly diagnosed multiple myeloma (NDMM) patients: primary results of the Intergroupe Francophone Du MyéLome (IFM) KRd phase II study. ASH Annual Meeting Abstracts A1142

40. Moreau P, Hulin C, Caillot D, Marit G, Perrot A, Garderet L, Facon T, Benboubker L, Karlin L, Tiab M, Arnulf B, Fermand JP, Leleu X, Touzeau C, Roussel M, Planche L, Minivielle S, Bene M, Avet-Loiseau H, Dejoie T, Attal M (2016) Ixazomib-lenalidomide-dexamethasone (IRd) combination before and after autologous stem cell transplantation (ASCT) followed by ixazomib maintenance in patients with newly diagnosed multiple myeloma (NDMM): a phase 2 study from the Intergroupe Francophone Du MyéLome (IFM). ASH Annual Meeting Abstracts A674

41. ECOG-ACRIN Cancer Research Group (2016) Bortezomib or carfilzomib with lenalidomide and dexamethasone in treating patients with newly diagnosed multiple myeloma. https://clinicaltrials.gov/ct2/show/NCT01863550?term=NCT01863550&rank=1 . Accessed June 2016

42. University of Leeds (2016) Use of thalidomide, lenalidomide, carfilzomib, bortezomib and vorinostat in the initial treatment of newly diagnosed multiple myeloma patients (Myeloma XI). https://clinicaltrials.gov/ct2/show/NCT01554852 . Accessed August 2016

43. Pawlyn C Davies FE Cairns DA Collett C Chalmers A Striha A Jones JR Garg M Allotey D Karunanithi K Milligan D Kaiser MF Jenner MW Cook G Russell NH Drayson MT Owen RG Gregory WM Jackson GH Morgan GJ Quadruplet vs sequential triplet induction therapy approaches to maximise response for newly diagnosed, transplant eligible, myeloma patients Blood 2015 126 189

44. Pawlyn C, Davies F, Cairns DA, Striha A, Waterhouse A, Collett C, Jones J, Kishore B, Garg M, Williams C, Karunanithi K, Lindsay J, Jenner M, Cook G, Kaiser M, Drayson M, Owen RG, Russell N, Gregory W, Morgan G, Jackson GH (2017) Quadruplet vs sequential triplet induction therapy for myeloma patients results of the myeloma XI study. Abstract S407. Haematologica 102(s2):1–882

45. Center UoHM (2016) A phase III trial on the effect of elotuzumab in VRD induction /consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma (GMMG-HD6). https://clinicaltrials.gov/ct2/show/NCT02495922?term=NCT02495922&rank=1 . Accessed June 2016

46. Landgren O Iskander K Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes J Intern Med 2017 281 4 365 382 10.1111/joim.12590 28205262

47. Rajkumar SV Myeloma today: disease definitions and treatment advances Am J Hematol 2016 91 1 90 100 10.1002/ajh.24236 26565896 PMC4715763

48. Sonneveld P, Beksac M, Van der Holt B, Dimopoulos M, Carella AM, Ludwig H, Driessen C, Wester R, Hajek R, Croockewit S, Troia R, Gay F, Cafro AM, De Rosa L, Fioritoni G, Mellqvist UH, Johnsen HE, Zweegman S, Wu KL, Parreira J, Schjesvold FH, D’Rozario J, Palumbo A, Cavo M (2016) Consolidation followed by maintenance therapy versus maintenance alone in newly diagnosed, transplant eligible patients with multiple myeloma (MM): a randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial). ASH Annual Meeting Abstracts A242

49. Stadtmauer E, Pasquini MC, Blackwell B, Knust K, Bashy A, Devine SM, Efebera YA, Ganguly S, Gasparetto C, Geller N, Giralt S, Hari P, Horowitz MM, Koreth J, Landau H, McCarthy P, McClune B, Nelson C, Qazilbash MH, Shah N, Vesole DH, Vij R, Vogl DT, Somlo G, Krishnan A (2016) Comparison of autologous hematopoietic cell transplant (autoHCT), bortezomib, lenalidomide (Len) and dexamethasone (RVD) consolidation with Len maintenance (ACM), tandem autoHCT with Len maintenance (TAM) and autoHCT with Len maintenance (AM) for up-front treatment of patients with multiple myeloma (MM): primary results from the randomized phase III trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702-StaMINA trial). ASH Annual Meeting Abstracts LBA-1

50. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L, Yakoub Agha I, Bourhis JH, Garderet L, Pegourie B, Dumontet C, Renaud M, Voillat L, Berthou C, Marit G, Monconduit M, Caillot D, Grobois B, Avet-Loiseau H, Moreau P, Facon T, Inter-Groupe Francophone du Myelome (2006) Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108(10):3289–3294. 10.1182/blood-2006-05-022962 10.1182/blood-2006-05-022962 16873668

51. Attal M, Palumbo A, Holstein SA, Lauwers-Cances V, Petrucci MT, Richardson PG, Hulin C, Tosi P, Anderson KC, Caillot D, Magarotto V, Moreau P, Marit G, Yu Z, McCarthy PL (2016) Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): a meta-analysis (MA) of overall survival (OS). J Clin Oncol 34(suppl; abstr 8001)

52. Sengsayadeth S Malard F Savani BN Garderet L Mohty M Posttransplant maintenance therapy in multiple myeloma: the changing landscape Blood Cancer J 2017 7 3 e545 10.1038/bcj.2017.23 28338672 PMC5380907

53. Jackson GH, Davies F, Pawlyn C, Cairns DA, Striha A, Waterhouse A, Jones J, Kishore B, Garg M, Williams C, Karunanithi K, Lindsay J, Jenner M, Cook G, Kaiser M, Drayson M, Owen RG, Russell N, Gregory W, Morgan GJ, NCRI Haemato-Oncology Clinical Studies Group (2017) Lenalidomide induction and maintenance therapy for transplant eligible myeloma patients: results of the Myeloma XI study. J Clin Oncol 35(15 suppl):8009. 10.1200/JCO.2017.35.15_suppl.8009

54. Celgene Ltd (2017) Revlimid (lenalidomide) summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000717/WC500056018.pdf . Accessed March 2018

55. Pulte ED, Dmytrijuk A, Nie L, Goldberg KB, McKee AE, Farrell AT, Pazdur R (2018) FDA approval summary: lenalidomide as maintenance therapy after autologous stem cell transplant in newly diagnosed multiple myeloma. Oncologist 23(6):734–739 10.1634/theoncologist.2017-0440 10.1634/theoncologist.2017-0440 PMC6067941 29438096

56. Goldschmidt H Lokhorst HM Mai EK van der Holt B Blau IW Zweegman S Weisel KC Vellenga E Pfreundschuh M Kersten MJ Scheid C Croockewit S Raymakers R Hose D Potamianou A Jauch A Hillengass J Stevens-Kroef M Raab MS Broijl A Lindemann HW Bos GMJ Brossart P van Marwijk KM Ypma P Duehrsen U Schaafsma RM Bertsch U Hielscher T Jarari L Salwender HJ Sonneveld P Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial Leukemia 2018 32 2 383 390 10.1038/leu.2017.211 28761118

57. Larocca A Palumbo A How I treat fragile myeloma patients Blood 2015 126 19 2179 2185 10.1182/blood-2015-05-612960 26324701

58. Palumbo A Bringhen S Liberati AM Caravita T Falcone A Callea V Montanaro M Ria R Capaldi A Zambello R Benevolo G Derudas D Dore F Cavallo F Gay F Falco P Ciccone G Musto P Cavo M Boccadoro M Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial Blood 2008 112 8 3107 3114 10.1182/blood-2008-04-149427 18505783

59. Mateos MV Oriol A Martinez-Lopez J Gutierrez N Teruel AI de Paz R Garcia-Larana J Bengoechea E Martin A Mediavilla JD Palomera L de Arriba F Gonzalez Y Hernandez JM Sureda A Bello JL Bargay J Penalver FJ Ribera JM Martin-Mateos ML Garcia-Sanz R Cibeira MT Ramos ML Vidriales MB Paiva B Montalban MA Lahuerta JJ Blade J Miguel JF Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial Lancet Oncol 2010 11 10 934 941 10.1016/S1470-2045(10)70187-X 20739218

60. Stewart AK Jacobus S Fonseca R Weiss M Callander NS Chanan-Khan AA Rajkumar SV Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma Blood 2015 126 11 1294 1301 10.1182/blood-2014-12-613927 26157076 PMC4566809

61. Hungria VT Crusoe EQ Maiolino A Bittencourt R Fantl D Maciel JF Pessoa de Magalhaes RJ Almeida MS Cury P Hisgashi F Peres AL Chiattone CS Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible Ann Hematol 2016 95 2 271 278 10.1007/s00277-015-2537-2 26518211

62. Magarotto V Bringhen S Offidani M Benevolo G Patriarca F Mina R Falcone AP De Paoli L Pietrantuono G Gentili S Musolino C Giuliani N Bernardini A Conticello C Pulini S Ciccone G Maisnar V Ruggeri M Zambello R Guglielmelli T Ledda A Liberati AM Montefusco V Hajek R Boccadoro M Palumbo A Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma Blood 2016 127 9 1102 1108 10.1182/blood-2015-08-662627 26729895

63. Hulin C, Belch A, Shustik C, Petrucci MT, Duhrsen U, Lu J, Song K, Rodon P, Pegourie B, Garderet L, Hunter H, Azais I, Eek R, Gisslinger H, Macro M, Dakhil S, Goncalves C, LeBlanc R, Romeril K, Royer B, Doyen C, Leleu X, Offner F, Leupin N, Houck V, Chen G, Ervin-Haynes A, Dimopoulos MA, Facon T (2016) Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial. J Clin Oncol 34(30):3609–3617 10.1200/JCO.2016.66.7295 10.1200/JCO.2016.66.7295 27325857

64. Durie BG Hoering A Abidi MH Rajkumar SV Epstein J Kahanic SP Thakuri M Reu F Reynolds CM Sexton R Orlowski RZ Barlogie B Dispenzieri A Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial Lancet 2017 389 10068 519 527 10.1016/S0140-6736(16)31594-X 28017406 PMC5546834

65. Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J (2018) Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med 378(6):518–528. 10.1056/NEJMoa1714678 10.1056/NEJMoa1714678 29231133

66. Mateos MV Martinez-Lopez J Hernandez MT Ocio EM Rosinol L Martinez R Teruel AI Gutierrez NC Martin Ramos ML Oriol A Bargay J Bengoechea E Gonzalez Y Perez de Oteyza J Gironella M Encinas C Martin J Cabrera C Paiva B Cedena MT Puig N Blade J Lahuerta JJ San-Miguel J Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM Blood 2016 127 4 420 425 10.1182/blood-2015-08-666537 26500339

67. Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, Offidani M, McCarthy P, Evangelista A, Lonial S, Zweegman S, Musto P, Terpos E, Belch A, Hajek R, Ludwig H, Stewart AK, Moreau P, Anderson K, Einsele H, Durie BG, Dimopoulos MA, Landgren O, San Miguel JF, Richardson P, Sonneveld P, Rajkumar SV (2015) Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 125(13):2068–2074. 10.1182/blood-2014-12-615187 10.1182/blood-2014-12-615187 PMC4375104 25628469

68. Engelhardt M Dold SM Ihorst G Zober A Moller M Reinhardt H Hieke S Schumacher M Wasch R Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores Haematologica 2016 101 9 1110 1119 10.3324/haematol.2016.148189 27479825 PMC5060028

69. Bonomo L Lue J Jagannath S Chari A The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution Cancer Med 2016 5 3 500 505 10.1002/cam4.620 26799254 PMC4799960

70. Mateos MV Oriol A Martinez-Lopez J Teruel AI Lopez de la Guia A Lopez J Bengoechea E Perez M Martinez R Palomera L de Arriba F Gonzalez Y Hernandez JM Granell M Bello JL Bargay J Penalver FJ Martin-Mateos ML Paiva B Montalban MA Blade J Lahuerta JJ San-Miguel JF GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? Blood 2014 124 12 1887 1893 10.1182/blood-2014-05-573733 25102853

71. Morgan GJ Schey SA Wu P Srikanth M Phekoo KJ Jenner M Davies FE Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients Br J Haematol 2007 137 3 268 269 10.1111/j.1365-2141.2007.06538.x 17408469

72. Sonneveld P Broijl A Treatment of relapsed and refractory multiple myeloma Haematologica 2016 101 4 396 406 10.3324/haematol.2015.129189 27033237 PMC5004403

73. Laubach J Garderet L Mahindra A Gahrton G Caers J Sezer O Voorhees P Leleu X Johnsen HE Streetly M Jurczyszyn A Ludwig H Mellqvist UH Chng WJ Pilarski L Einsele H Hou J Turesson I Zamagni E Chim CS Mazumder A Westin J Lu J Reiman T Kristinsson S Joshua D Roussel M O'Gorman P Terpos E McCarthy P Dimopoulos M Moreau P Orlowski RZ Miguel JS Anderson KC Palumbo A Kumar S Rajkumar V Durie B Richardson PG Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group Leukemia 2016 30 5 1005 1017 10.1038/leu.2015.356 26710887

74. Cook G, Ashcroft AJ, Cairns DA, Williams CD, Brown JM, Cavenagh JD, Snowden JA, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Chown S, Heartin E, O'Connor S, Drayson MT, Hockaday A, Morris TC, National Cancer Research Institute Haemato-oncology Clinical Studies Group (2016) The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF myeloma X relapse [intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol 3(7):e340–e351. 10.1016/S2352-3026(16)30049-7 10.1016/S2352-3026(16)30049-7 27374467

75. Cook G, Williams C, Brown JM, Cairns DA, Cavenagh J, Snowden JA, Ashcroft AJ, Fletcher M, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Chalmers A, O'Connor S, Drayson MT, Morris TC, National Cancer Research Institute Haemato-oncology Clinical Studies Group (2014) High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI myeloma X relapse [intensive trial]): a randomised, open-label, phase 3 trial. Lancet Oncol 15(8):874–885. 10.1016/S1470-2045(14)70245-1 10.1016/S1470-2045(14)70245-1 24948586

76. Singh Abbi KK Zheng J Devlin SM Giralt S Landau H Second autologous stem cell transplant: an effective therapy for relapsed multiple myeloma Biol Blood Marrow Transplant 2015 21 3 468 472 10.1016/j.bbmt.2014.11.677 25529381

77. Garderet L, Iacobelli S, van Biezen A, Koster L, Dreger P, Johanssen J-E, Leleu X, Potter M, Krejcj M, Peschel C, Radocha J, Ganser A, Metzner B, Paoli N, Schäfer-Eckart K, Pohlreich D, Lenain P, Grasso M, Caillot D, Einsele H, Sengeloev H, Meuleman N, Ciceri F, Schönland S, Kröger N (2016) Outcome of third salvage autologous stem cell transplantation in multiple myeloma. ASH Annual Meeting Abstracts A993

78. Mikhael JR A practical approach to relapsed multiple myeloma Hematology Am Soc Hematol Educ Program 2014 2014 1 262 267 10.1182/asheducation-2014.1.262 25696865

79. Garderet L Iacobelli S Moreau P Dib M Lafon I Niederwieser D Masszi T Fontan J Michallet M Gratwohl A Milone G Doyen C Pegourie B Hajek R Casassus P Kolb B Chaleteix C Hertenstein B Onida F Ludwig H Ketterer N Koenecke C van Os M Mohty M Cakana A Gorin NC de Witte T Harousseau JL Morris C Gahrton G Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 randomized phase III trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation J Clin Oncol 2012 30 20 2475 2482 10.1200/JCO.2011.37.4918 22585692

80. Baz R Martin TG Alsina M Shain KH Cho HJ Wolf JL Mahindra A Chari A Sullivan DM Nardelli LA Lau K Zhao X Lin H-Y Jagannath S Pomalidomide, cyclophosphamide, and dexamethasone is superior to pomalidomide and dexamethasone in relapsed and refractory myeloma: results of a multicenter randomized phase II study Blood 2014 124 303 10.1182/blood-2015-11-682518 26932802

81. Glasmacher A Hahn C Hoffmann F Naumann R Goldschmidt H von Lilienfeld-Toal M Orlopp K Schmidt-Wolf I Gorschluter M A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma Br J Haematol 2006 132 5 584 593 10.1111/j.1365-2141.2005.05914.x 16445831

82. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foa R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD, Multiple Myeloma Study Investigators (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357(21):2123–2132. 10.1056/NEJMoa070594 10.1056/NEJMoa070594 18032762

83. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD, Multiple Myeloma Study Investigators (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357(21):2133–2142. 10.1056/NEJMoa070596 10.1056/NEJMoa070596 18032763

84. Amgen Ltd (2017) Second phase 3 study shows KYPROLIS® (carfilzomib) regimen significantly improves overall survival in patients with relapsed multiple myeloma. https://www.amgen.com/media/news-releases/2017/07/second-phase-3-study-shows-kyprolis-carfilzomib-regimen-significantly-improves-overall-survival-in-patients-with-relapsed-multiple-myeloma/ . Accessed 4 October 2017

85. Takeda Pharma A/S (2016) Ninlaro (ixazomib) summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003844/WC500217620.pdf . Accessed December 2016

86. Celgene Ltd (2015) Imnovid (pomalidomide) summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002682/WC500147717.pdf . Accessed June 2016

87. Lacy MQ LaPlant BR Laumann KM Kumar S Gertz MA Hayman SR Buadi F Dispenzieri A Lust JA Kapoor P Leung N Russell SJ Dingli D Gonsalves WI Fonseca R Bergsagel PL Roy V Sher T Ailawadhi S Chanan-Khan A Stewart AK Reeder CB Rajkumar SV Mikhael JR Pomalidomide, bortezomib and dexamethasone (PVD) for patients with relapsed lenalidomide refractory multiple myeloma (MM) Blood 2014 124 304 10.1182/blood-2017-05-782961 PMC5606008 28684537

88. Bringhen S, Magarotto V, Liberati AM, Belotti A, Larocca A, Gilestro M, Bonello F, Gaidano G, Bertazzoni P, Stocchi R, Ribolla R, Di Sano C, Patriarca F, Passera R, De Paoli L, Oliva S, Cafro AM, Sonneveld P, Palumbo A, Boccadoro M (2016) A multicenter, open label phase I/II study of carfilzomib, pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma (MM) patients. ASH Annual Meeting Abstracts A1145

89. Plesner T Arkenau HT Gimsing P Krejcik J Lemech C Minnema MC Lassen U Laubach JP Palumbo A Lisby S Basse L Wang J Sasser AK Guckert ME de Boer C Khokhar NZ Yeh H Clemens PL Ahmadi T Lokhorst HM Richardson PG Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma Blood 2016 128 1821 1828 10.1182/blood-2016-07-726729 27531679 PMC5054695

90. Lokhorst HM Plesner T Laubach JP Nahi H Gimsing P Hansson M Minnema MC Lassen U Krejcik J Palumbo A van de Donk NW Ahmadi T Khan I Uhlar CM Wang J Sasser AK Losic N Lisby S Basse L Brun N Richardson PG Targeting CD38 with daratumumab monotherapy in multiple myeloma N Engl J Med 2015 373 13 1207 1219 10.1056/NEJMoa1506348 26308596

91. Jakubowiak A Offidani M Pegourie B De La Rubia J Garderet L Laribi K Bosi A Marasca R Laubach J Mohrbacher A Carella AM Singhal AK Tsao LC Lynch M Bleickardt E Jou YM Robbins M Palumbo A Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM Blood 2016 127 23 2833 2840 10.1182/blood-2016-01-694604 27091875 PMC4900953

92. Janssen Research & Development LLC (2016) Addition of daratumumab to combination of bortezomib and dexamethasone in participants with relapsed or refractory multiple myeloma. https://clinicaltrials.gov/ct2/show/NCT02136134?term=NCT02136134&rank=1 . Accessed June 2016

93. Bristol-Myers Squibb (2016) Phase III study of lenalidomide and dexamethasone with or without elotuzumab to treat relapsed or refractory multiple myeloma (ELOQUENT-2). https://clinicaltrials.gov/ct2/show/NCT01239797?term=NCT01239797&rank=1 . Accessed June 2016

94. Janssen Research & Development LLC (2016) A study comparing daratumumab, lenalidomide, and dexamethasone with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma. https://clinicaltrials.gov/ct2/show/NCT02076009?term=NCT02076009&rank=1 . Accessed June 2016

95. Lonial S Durie B Palumbo A San-Miguel J Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives Leukemia 2016 30 3 526 535 10.1038/leu.2015.223 26265184 PMC4777772

96. Amgen Ltd (2015) Kyprolis (carfilzomib) summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003790/WC500197692pdf Accessed June 2016

97. Janssen-Cillag NV (2016) Velcade (bortezomib) summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000539/WC500048471.pdf . Accessed June 2016

98. Lacy MQ Hayman SR Gertz MA Short KD Dispenzieri A Kumar S Greipp PR Lust JA Russell SJ Dingli D Zeldenrust S Fonseca R Bergsagel PL Roy V Mikhael JR Stewart AK Laumann K Allred JB Mandrekar SJ Rajkumar SV Buadi F Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM) Leukemia 2010 24 11 1934 1939 10.1038/leu.2010.190 20827286 PMC2978257

99. Dimopoulos MA Palumbo A Corradini P Cavo M Delforge M Di Raimondo F Weisel KC Oriol A Hansson M Vacca A Blanchard MJ Goldschmidt H Doyen C Kaiser M Petrini M Anttila P Cafro AM Raymakers R San-Miguel J de Arriba F Knop S Rollig C Ocio EM Morgan G Miller N Simcock M Peluso T Herring J Sternas L Zaki MH Moreau P Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma Blood 2016 128 4 497 503 10.1182/blood-2016-02-700872 27226434 PMC5009959

100. Shah JJ Stadtmauer EA Abonour R Cohen AD Bensinger WI Gasparetto C Kaufman JL Lentzsch S Vogl DT Gomes CL Pascucci N Smith DD Orlowski RZ Durie BG Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma Blood 2015 126 20 2284 2290 10.1182/blood-2015-05-643320 26384354 PMC4643003

101. Chari A Suvannasankha A Fay JW Arnulf B Kaufman JL Ifthikharuddin JJ Weiss BM Krishnan A Lentzsch S Comenzo R Wang J Nottage K Chiu C Khokhar NZ Ahmadi T Lonial S Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma Blood 2017 130 8 974 981 10.1182/blood-2017-05-785246 28637662 PMC5570682

102. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P (2015) Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol 33(26):2863–2869. 10.1200/JCO.2015.61.2267 10.1200/JCO.2015.61.2267 PMC4846284 26240224

103. Sonneveld P Avet-Loiseau H Lonial S Usmani S Siegel D Anderson KC Chng WJ Moreau P Attal M Kyle RA Caers J Hillengass J San Miguel J van de Donk NW Einsele H Blade J Durie BG Goldschmidt H Mateos MV Palumbo A Orlowski R Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group Blood 2016 127 24 2955 2962 10.1182/blood-2016-01-631200 27002115 PMC4920674

104. Dispenzieri A Myeloma: management of the newly diagnosed high-risk patient Hematology Am Soc Hematol Educ Program 2016 2016 1 485 494 10.1182/asheducation-2016.1.485 27913520 PMC6142458

105. Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, Cook G, Feyler S, Johnson PR, Rudin C, Drayson MT, Owen RG, Ross FM, Russell NH, Jackson GH, Child JA, National Cancer Research Institute Haematological Oncology Clinical Studies Group (2012) Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC myeloma IX randomized trial results. Haematologica 97(3):442–450. 10.3324/haematol.2011.043372 10.3324/haematol.2011.043372 PMC3291601 22058209

106. Lonial S Boise LH Kaufman J How I treat high-risk myeloma Blood 2015 126 13 1536 1543 10.1182/blood-2015-06-653261 26272217

107. Offidani M, Corvatta L, Bringhen S, Gentili S, Troia R, Maracci L, Larocca A, Palumbo A, Leoni P (2016) Impact of cytogenetic risk on PFS2 of patients treated with different therapy sequences: results of a post-hoc analysis

108. Dimopoulos MA Weisel KC Song KW Delforge M Karlin L Goldschmidt H Moreau P Banos A Oriol A Garderet L Cavo M Ivanova V Alegre A Martinez-Lopez J Chen C Spencer A Knop S Bahlis NJ Renner C Yu X Hong K Sternas L Jacques C Zaki MH San Miguel JF Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone Haematologica 2015 100 10 1327 1333 10.3324/haematol.2014.117077 26250580 PMC4591765

109. Leleu X, Karlin L, Macro M, Hulin C, Garderet L, Roussel M, Arnulf B, Pegourie B, Kolb B, Stoppa AM, Brechiniac S, Marit G, Thielemans B, Onraed B, Mathiot C, Banos A, Lacotte L, Tiab M, Dib M, Fuzibet JG, Petillon MO, Rodon P, Wetterwald M, Royer B, Legros L, Benboubker L, Decaux O, Escoffre-Barbe M, Caillot D, Fermand JP, Moreau P, Attal M, Avet-Loiseau H, Facon T, Intergroupe Francophone du Myelome (2015) Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results. Blood 125(9):1411–1417. 10.1182/blood-2014-11-612069 10.1182/blood-2014-11-612069 25575538

110. Avet-Loiseau H Fonseca R Siegel D Dimopoulos MA Spicka I Masszi T Hajek R Rosinol L Goranova-Marinova V Mihaylov G Maisnar V Mateos MV Wang M Niesvizky R Oriol A Jakubowiak A Minarik J Palumbo A Bensinger W Kukreti V Ben-Yehuda D Stewart AK Obreja M Moreau P Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma Blood 2016 128 9 1174 1180 10.1182/blood-2016-03-707596 27439911 PMC5009511

111. Mateos M, Estell J, Barreto W, Corradini P, Min C-K, Medvedova E, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Casneuf T, Chiu C, Sasser AK, Nooka AK (2016) Efficacy of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory myeloma based on prior lines of therapy: updated analysis of CASTOR. Blood 128(22):92–5969 (Abstract 1150)

112. Usmani S, Dimopoulos M, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, Takezako N, Khokhar N, Guckert M, Wu K, Qin X, Casneuf T, Chiu C, Sasser AK, San Miguel J (2016) Efficacy of daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients with 1 to 3 prior lines of therapy: updated analysis of POLLUX. Blood 128(22):92–5969 (Abstract 1151)

113. Hájek R Jarkovsky J Bouwmeester W Treur M DeCosta L Campioni M Delforge M Raab MS Schoen P Szabo Z Lucie B Gonzalez-McQuire S Exploration of survival stratification of patients with multiple myeloma after first relapse using real world data Blood 2016 128 22 2417 2417

114. Decaux O Lode L Magrangeas F Charbonnel C Gouraud W Jezequel P Attal M Harousseau JL Moreau P Bataille R Campion L Avet-Loiseau H Minvielle S Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome J Clin Oncol 2008 26 29 4798 4805 10.1200/JCO.2007.13.8545 18591550

115. Kuiper R Broyl A de Knegt Y van Vliet MH van Beers EH van der Holt B el Jarari L Mulligan G Gregory W Morgan G Goldschmidt H Lokhorst HM van Duin M Sonneveld P A gene expression signature for high-risk multiple myeloma Leukemia 2012 26 11 2406 2413 10.1038/leu.2012.127 22722715

116. Shaughnessy JD Jr Zhan F Burington BE Huang Y Colla S Hanamura I Stewart JP Kordsmeier B Randolph C Williams DR Xiao Y Xu H Epstein J Anaissie E Krishna SG Cottler-Fox M Hollmig K Mohiuddin A Pineda-Roman M Tricot G van Rhee F Sawyer J Alsayed Y Walker R Zangari M Crowley J Barlogie B A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1 Blood 2007 109 6 2276 2284 10.1182/blood-2006-07-038430 17105813

117. Mulligan G Lichter DI Di Bacco A Blakemore SJ Berger A Koenig E Bernard H Trepicchio W Li B Neuwirth R Chattopadhyay N Bolen JB Dorner AJ van de Velde H Ricci D Jagannath S Berenson JR Richardson PG Stadtmauer EA Orlowski RZ Lonial S Anderson KC Sonneveld P San Miguel JF Esseltine DL Schu M Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy Blood 2014 123 5 632 639 10.1182/blood-2013-05-504340 24335104 PMC4123425

118. Walker BA Boyle EM Wardell CP Murison A Begum DB Dahir NM Proszek PZ Johnson DC Kaiser MF Melchor L Aronson LI Scales M Pawlyn C Mirabella F Jones JR Brioli A Mikulasova A Cairns DA Gregory WM Quartilho A Drayson MT Russell N Cook G Jackson GH Leleu X Davies FE Morgan GJ Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma J Clin Oncol 2015 33 33 3911 3920 10.1200/JCO.2014.59.1503 26282654 PMC6485456

119. Kumar S Kaufman JL Gasparetto C Mikhael J Vij R Pegourie B Benboubker L Facon T Amiot M Moreau P Punnoose EA Alzate S Dunbar M Xu T Agarwal SK Enschede SH Leverson JD Ross JA Maciag PC Verdugo M Touzeau C Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma Blood 2017 130 22 2401 2409 10.1182/blood-2017-06-788786 29018077

120. Kumar S Flinn I Richardson PG Hari P Callander N Noga SJ Stewart AK Turturro F Rifkin R Wolf J Estevam J Mulligan G Shi H Webb IJ Rajkumar SV Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma Blood 2012 119 19 4375 4382 10.1182/blood-2011-11-395749 22422823

121. Intergroupe Francophone du Myelome (2016) A study to evaluate daratumumab in transplant eligible participants with previously untreated multiple myeloma (Cassiopeia). https://clinicaltrials.gov/ct2/show/NCT02541383?term=NCT02541383&rank=1 . Accessed June 2016

122. Bristol-Myers Squibb (2016) Study of combinations of nivolumab, elotuzumab, pomalidomide and dexamethasone in multiple myeloma (CheckMate 602). https://clinicaltrials.gov/ct2/show/NCT02726581?term=NCT02726581&rank=1 . Accessed June 2016

123. Sonneveld P De Wit E Moreau P How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients? Crit Rev Oncol Hematol 2017 112 153 170 10.1016/j.critrevonc.2017.02.007 28325256

124. Gaultney JG Franken MG Tan SS Redekop WK Huijgens PC Sonneveld P Uyl-de Groot CA Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents J Clin Pharm Ther 2013 38 1 41 47 10.1111/jcpt.12020 23126374